Clinical Trial

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-11-04; most recent amendment 2025-11-07.
Trial Details
NCT Number NCT04150614
Lead Sponsor University of Illinois at Chicago
Conditions Nausea With Vomiting Chemotherapy-Induced
Enrollment 90 participants
Start Date 2020-05-14
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-11-12